Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022

<br /> Biohaven to Discuss First Quarter 2022 Financial Results and Recent Business Developments on May 11, 2022<br />

PR Newswire

NEW HAVEN, Conn.

,

May 9, 2022

/PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, plans to hold its upcoming first quarter 2022 earnings call and webcast, reporting financial results for the quarter ended

March 31, 2022

, and provide a review of recent accomplishments and anticipated upcoming milestones, on

Wednesday, May 11, 2022

at

8:30 a.m. ET

. The earnings call and webcast will follow Biohaven’s issuance of its first quarter 2022 earnings release and the filing of its quarterly report on Form 10-Q for the quarter ended

March 31, 2022

on

Tuesday, May 10, 2022

.

To access the call on

May 11, 2022

, please dial 877-407-9120 (domestic) or 412-902-1009 (international). The conference call webcast and accompanying slide presentation can be accessed through the “Investors” section of Biohaven’s website at

www.biohavenpharma.com

. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the call will be made available for two weeks following the conference call. To hear a replay of the call, dial 877-660-6853 (domestic) or 201-612-7415 (international) with conference ID 13728089. An archived webcast will be available on Biohaven’s website.

About Biohaven

Biohaven

is a global commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to improve the lives of patients with debilitating neurological and

neuropsychiatric

diseases, including rare disorders.

Biohaven’s Neuroinnovation

™ portfolio includes FDA-approved

Nurtec

®

ODT

(

rimegepant

) for the acute and preventive treatment of migraine (

EMA-approved

as

Vydura

® for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks per month) and a broad pipeline of late-stage product candidates across five distinct mechanistic platforms:

CGRP

receptor antagonism for the acute and preventive treatment of migraine and other

CGRP-mediated

diseases; glutamate modulation for obsessive-compulsive disorder and

spinocerebellar

ataxia;

myeloperoxidase

(

MPO

) inhibition for

amyotrophic

lateral sclerosis; Kv7 ion channel activators for focal epilepsy and neuronal

hyperexcitability

, and

myostatin

inhibition for neuromuscular diseases. More information about

Biohaven

is available at

www.biohavenpharma.com

.

NURTEC, NURTEC ODT and VYDURA are registered trademarks of Biohaven Pharmaceutical Ireland DAC. Neuroinnovation is a trademark of Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Contact:

Jennifer Porcelli

Vice President, Investor Relations

[email protected]